

Allarity Therapeutics, Inc. (ALLR)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001860657

Allarity Therapeutics, Inc.		
ALLR; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$18.3M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	late filer, thin data not computable: distress, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Mar 30, 2026 193 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026	
Last close	\$1.00 2026-10-07; market equity \$15.9M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell's sensitivity to a specific cancer therapeutic.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 94.7						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		17.5%	(6.6%)	94.7	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 72.7						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(23.25)	(0.31)	76.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.13x	2.96x	69.5	839	2025-12-31
Growth and financing, sleeve percentile 18.4						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 1
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 3
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		7.9%	2.1%	35.0	704	2025-12-31
Net share issuance, one year		(7.0%)	2.5%	1.9	634	2026-03-30

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-07 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(10.8%)	8.0%	39

Distance from 52-week high	(44.5%)	(31.4%)	33
EBIT to enterprise value	(949.4%)	(1.5%)	2
Free cash flow yield	(94.9%)	(1.0%)	5
Book value to price	0.23	0.28	44
Sales to price	0.02	0.31	9
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.33)	(0.14)	39

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$17.0M
Operating cash flow, four quarters	-\$13.7M
Months of runway	14.9
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$82,539

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$11.2M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$14.8M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
3	assets	us-gaap:Assets	\$18.3M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
4	assets	us-gaap:Assets	\$22.6M	2024-12-31	2026-03-30	10-K	0001437749-26-010310
5	current assets	us-gaap:AssetsCurrent	\$17.9M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
6	current liabilities	us-gaap:LiabilitiesCurrent	\$8.4M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$130.2M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
8	operating income	us-gaap:OperatingIncomeLoss	-\$12.6M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
9	book equity	us-gaap:StockholdersEquity	\$9.8M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
10	liabilities	us-gaap:Liabilities	\$8.4M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
11	operating income	us-gaap:OperatingIncomeLoss	-\$17.1M	2023-12-31	2025-03-31	10-K	0001437749-25-010198
12	interest expense	us-gaap:InterestAndDebtExpense	\$217,000	2023-12-31	2024-03-08	10-K	0001213900-24-020864
13	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$320,000	2025-12-31	2026-03-30	10-K	0001437749-26-010310
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$298,000	2024-12-31	2026-03-30	10-K	0001437749-26-010310
15	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$9,000	2024-12-31	2025-03-31	10-K	0001437749-25-010198
16	operating income	us-gaap:OperatingIncomeLoss	-\$27.2M	2024-12-31	2026-03-30	10-K	0001437749-26-010310
17	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$14.9M	2025-12-31	2026-03-30	10-K	0001437749-26-010310
18	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$381,000	2024-12-31	2026-03-30	10-K	0001437749-26-010310
19	current assets	us-gaap:AssetsCurrent	\$22.3M	2024-12-31	2026-03-30	10-K	0001437749-26-010310
20	current liabilities	us-gaap:LiabilitiesCurrent	\$10.8M	2024-12-31	2026-03-30	10-K	0001437749-26-010310
21	current assets	us-gaap:AssetsCurrent	\$2.0M	2023-12-31	2025-03-31	10-K	0001437749-25-010198
22	current liabilities	us-gaap:LiabilitiesCurrent	\$14.2M	2023-12-31	2025-03-31	10-K	0001437749-25-010198
23	assets	us-gaap:Assets	\$11.9M	2023-12-31	2025-03-31	10-K	0001437749-25-010198
24	assets	us-gaap:Assets	\$14.5M	2022-12-31	2024-03-08	10-K	0001213900-24-020864
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	15,818,980	2026-03-30	2026-03-30	10-K	0001437749-26-010310
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	17,014,737	2025-03-31	2025-03-31	10-K	0001437749-25-010198